Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:31:51 2024-05-23 am EDT			5-day change	1st Jan Change
42.26 ^USD	-1.42%		-7.57%	+4.86%

May. 13	Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating	MT
May. 10	Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target	MT

Soleno Therapeutics, Inc. Announces Gwen Melincoff, Intends Not Intend to Stand for Re-Election as Director

April 22, 2024 at 04:16 pm EDT

On April 17, 2024, in connection with the determination by the Board of Directors of Soleno Therapeutics, Inc. at the Company?s 2024 Annual Meeting of Stockholders Gwen Melincoff, a current director, notified the Company that she does not intend to stand for re-election to the Board at the 2024 AGM.

Latest news about Soleno Therapeutics, Inc.

Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating	May. 13	MT
Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target	May. 10	MT
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Soleno Therapeutics Prices $138 Million Stock Offering	May. 03	MT
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome	Apr. 30	CI
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	Apr. 29	MT
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline	Apr. 29	DJ
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome	Apr. 29	CI
Soleno Therapeutics, Inc. Announces Gwen Melincoff, Intends Not Intend to Stand for Re-Election as Director	Apr. 22	CI
Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing	Apr. 04	MT
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Piper Sandler Starts Soleno Therapeutics With Overweight Rating, $93 Price Target	Feb. 05	MT
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	Jan. 24	MT
Soleno Therapeutics Strengthens Leadership Team with Key Appointments	Jan. 24	CI
Stifel Starts Soleno Therapeutics With Buy Rating, $63 Price Target	Jan. 23	MT
Soleno Therapeutics Files Mixed Shelf	Jan. 03	MT
Oppenheimer Lifts Price Target on Soleno Therapeutics to $47 From $44, Maintains Outperform Rating	Jan. 02	MT
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) added to S&P Biotechnology Select Industry Index	Dec. 18	CI
Soleno Therapeutics Insider Sold Shares Worth $1,412,431, According to a Recent SEC Filing	Dec. 15	MT
Soleno Therapeutics Insider Sold Shares Worth $1,182,828, According to a Recent SEC Filing	Dec. 14	MT
Soleno Therapeutics Insider Sold Shares Worth $222,177, According to a Recent SEC Filing	Dec. 01	MT
Soleno Therapeutics Insider Sold Shares Worth $1,471,049, According to a Recent SEC Filing	Dec. 01	MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $44 From $39, Maintains Outperform Rating	Nov. 09	MT

Chart Soleno Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCRâs mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.87 USD

Average target price

68.14 USD

Spread / Average Target

+58.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOLENO THERAPEUTICS, INC.	+4.86%	1.56B
VERTEX PHARMACEUTICALS INCORPORATED	+10.56%	115B
REGENERON PHARMACEUTICALS, INC.	+12.31%	106B
BIONTECH SE	-5.38%	24.69B
ARGENX SE	-1.43%	21.97B
GENMAB A/S	-4.87%	19.27B
BEIGENE, LTD.	-11.04%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.95%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.62%	12.13B

Bio Therapeutic Drugs